Life Sciences Venture Capital Monitor – Europe 09/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 09/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of September 2022 we identify the following current VC trends in Europe:

  • In 2022, overall Life Sciences funding has reached EUR 7,887m so far
  • Top 5 Deals exceed EUR 140m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Bpifrance (France) dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • Biotech received 43% of the total investment volume, (no change compared to the previous month)
  • Oncology still dominates as the top indication in Biotechnology

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link

Share
[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]